<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091178</url>
  </required_header>
  <id_info>
    <org_study_id>ICM2013/06</org_study_id>
    <nct_id>NCT04091178</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer</brief_title>
  <acronym>OPTIVIT</acronym>
  <official_title>A PHASE II Multicentric Trial Evaluating a High Dose Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer Treated by Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open clinical trial not randomized, multicentric. This study search to evaluate vitamin D
      supplementation efficacy at high dose (UVEDOSE, colecalciferol, oral solution at 100 000 UI)
      of vitamin D on day 1 of each cycles for breast cancer treated adjuvant chemotherapy.

      A calcium supplementation will be prescribed in parallel.

      An initial dosage of 25OH vitamin D rate will be done and a vitamin-calcic dosage will done
      on day 1 of every cycles of chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2013</start_date>
  <completion_date type="Actual">March 16, 2017</completion_date>
  <primary_completion_date type="Actual">June 11, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A phase 2 clinical trial not randomized</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalisation of Vitamin D level</measure>
    <time_frame>from the Cycle 1 to cycle 6 (each cycle is 21 days)</time_frame>
    <description>percentage of vitamin D level normalisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>initial vitamin D and calcium level</measure>
    <time_frame>at cycle 1( one cycle is 21 days)</time_frame>
    <description>blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>normalization of 25-OHD (vitamin D)</measure>
    <time_frame>at FU 6,12,18,24 months after the first dose of vitamin D</time_frame>
    <description>blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverses events rates</measure>
    <time_frame>from cycle 1 to follow-up 24 months (one cycle is 21 days)</time_frame>
    <description>graded based on NCI-CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vitamin D and calcium level</measure>
    <time_frame>from cycle 1 to 24 months (one cycle is 21 days)</time_frame>
    <description>blood test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>VITAMIN D SUPPLEMENTATION ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On day 1 of every chemotherapy cycle, the patient will be receive an oral solution of vitamin D (UVEDOSE/calciferol).
In parallel,a calcium supplementation is prescribed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VITAMIN D</intervention_name>
    <description>ORAL SOLUTION (2 ml) at 100.000 UI</description>
    <arm_group_label>VITAMIN D SUPPLEMENTATION ARM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast adenocarcinoma should receive 6 cycles of adjuvant chemotherapy

          -  Women ≥ 18 years old (no age limit)

          -  Performance status :0 or 1

          -  Patients must be affiliated to a Social Security System

          -  Signed informed consent obtained before any study specific procedures.

          -  Vitamin D deficiency confirmed ( vitamin D result must be &lt; at 30 ng/ml)

        Exclusion Criteria:

          -  Metastatic disease

          -  Patients with previous or concomitant other (not breast cancer) malignancy within the
             past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or
             in situ carcinoma of the cervix. Patients who have had a previous other malignancy
             must have been disease free for at least five years

          -  calcium or colecalciferol contraindications (vitamin D hypersensitivity - disease or
             an other condition result in hypercalcaemia or hypercalciuria -Calcic lithiasis- high
             vitamin D level)

          -  Presence of the following diseases in the last 3 years : endocrinal disease, A
             phosphor calcic disorder treated by vitamin D supplementation at 1000 UI/day or more
             (this patient who have received a dose &lt; 1000 UI/day, will be included after have to
             stop Vitamin D at least 48 hours ) - Osteopenia or osteoporosis confirmed treated

          -  Concomittant treatment with an other experimental product

          -  Pregnant or breastfeeding women

          -  Legal incapacity or physical, psychological or mental status interfering with the
             patient's ability to sign the informed consent or to terminate the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WILLIAM JACOT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du cancer de Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC. Vitamin D: current status and perspectives. Clin Chem Lab Med. 2009;47(2):120-7. doi: 10.1515/CCLM.2009.036. Review.</citation>
    <PMID>19099529</PMID>
  </results_reference>
  <results_reference>
    <citation>Sinotte M, Diorio C, Bérubé S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr. 2009 Feb;89(2):634-40. doi: 10.3945/ajcn.2008.26445. Epub 2008 Dec 30.</citation>
    <PMID>19116321</PMID>
  </results_reference>
  <results_reference>
    <citation>Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. Review.</citation>
    <PMID>17634462</PMID>
  </results_reference>
  <results_reference>
    <citation>Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005 May 11;293(18):2257-64. Review.</citation>
    <PMID>15886381</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007 Aug 25;370(9588):657-66. Review. Erratum in: Lancet. 2012 Sep 1;380(9844):806.</citation>
    <PMID>17720017</PMID>
  </results_reference>
  <results_reference>
    <citation>Roux C, Bischoff-Ferrari HA, Papapoulos SE, de Papp AE, West JA, Bouillon R. New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion. Curr Med Res Opin. 2008 May;24(5):1363-70. doi: 10.1185/030079908X301857 . Epub 2008 Apr 2. Review.</citation>
    <PMID>18387220</PMID>
  </results_reference>
  <results_reference>
    <citation>Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004 Apr 28;291(16):1999-2006. Review.</citation>
    <PMID>15113819</PMID>
  </results_reference>
  <results_reference>
    <citation>Abbas S, Nieters A, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res. 2008;10(2):R31. doi: 10.1186/bcr1994. Epub 2008 Apr 17.</citation>
    <PMID>18419802</PMID>
  </results_reference>
  <results_reference>
    <citation>Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study. Carcinogenesis. 2008 Jan;29(1):93-9. Epub 2007 Oct 31.</citation>
    <PMID>17974532</PMID>
  </results_reference>
  <results_reference>
    <citation>Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O'Dea AP, Klemp JR, Fabian CJ. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat. 2010 Jan;119(1):111-8. doi: 10.1007/s10549-009-0495-x. Epub 2009 Aug 5.</citation>
    <PMID>19655244</PMID>
  </results_reference>
  <results_reference>
    <citation>Peppone LJ, Huston AJ, Reid ME, Rosier RN, Zakharia Y, Trump DL, Mustian KM, Janelsins MC, Purnell JQ, Morrow GR. The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res Treat. 2011 May;127(1):171-7. doi: 10.1007/s10549-011-1415-4. Epub 2011 Mar 8.</citation>
    <PMID>21384167</PMID>
  </results_reference>
  <results_reference>
    <citation>Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol. 2009 Aug 1;27(22):3605-10. doi: 10.1200/JCO.2008.20.2549. Epub 2009 Jun 22.</citation>
    <PMID>19546403</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

